Meeting
2011 ASCO Annual Meeting
Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor–positive (HR+) HER2-negative (HER2–) advanced breast cancer (ABC).
Authors
B. Moy
Massachusetts General Hospital, Boston, MA
B. Moy , F. Lebrun , M. Bellet , L. Chow , I. Lang , B. Xu , R. A. Badwe , D. L. Hershman , E. Leip , N. Bardy-Bouxin , L. Duvillie , P. Neven
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
ER+
Clinical Trial Registration Number
NCT00793546
Citation
J Clin Oncol 29: 2011 (suppl; abstr 631)
Abstract #
631
Poster Bd #
13A
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
First Author: Wolfgang Janni
Poster
2022 ASCO Gastrointestinal Cancers Symposium
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
First Author: Samuel J Klempner
Poster
2020 ASCO Virtual Scientific Program
A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer.
First Author: Erika Paige Hamilton
Poster
2019 ASCO Annual Meeting
First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results.
First Author: Joyce O'Shaughnessy